Avience Biomedicals (NSE:AVIENCE) Total Stockholders Equity: ₹227.8 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
18 GF Score
Price ₹250.90
! 3 Warning Signs
View Full Analysis

What is Avience Biomedicals Total Stockholders Equity?

Avience Biomedicals NSE:AVIENCE +1.17% 18 Total Stockholders Equity is ₹227.8 Mil as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Avience Biomedicals's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ₹227.8 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Avience Biomedicals's Book Value per Share for the quarter that ended in Mar. 2025 was ₹41.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Avience Biomedicals's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.97.

Avience Biomedicals  (NSE:AVIENCE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Avience Biomedicals's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(227.771-0)/5.485
=41.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Avience Biomedicals's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(123.076 + 98.496) / 227.771
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Total Stockholders Equity Related Terms

Avience Biomedicals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Total Stockholders Equity Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
Total Stockholders Equity
40.70 62.11 227.77

Avience Biomedicals Semi-Annual Data
Mar23 Mar24 Mar25
Total Stockholders Equity 40.70 62.11 227.77
NSE:AVIENCE
18GF Score
Avience Biomedicals Ltd NSE:AVIENCE
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of ₹227.8 Mil mean?
Avience Biomedicals (NSE:AVIENCE) has a Total Stockholders Equity of ₹227.8 Mil as of Mar. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Avience Biomedicals and its competitors.
Is Avience Biomedicals' Total Stockholders Equity too high?
Avience Biomedicals' current Total Stockholders Equity is ₹227.8 Mil. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Total Stockholders Equity compare to ABT and SYK?
Avience Biomedicals' Total Stockholders Equity of ₹227.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Avience Biomedicals and its competitors. Avience Biomedicals's current Total Stockholders Equity is ₹227.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Total Stockholders Equity of ₹227.8 Mil. The current Total Stockholders Equity is ₹227.8 Mil. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Total Stockholders Equity is ₹227.8 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score

Get the complete analysis for NSE:AVIENCE

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹250.90
Price